Shield Therapeutics (LSE:STX) 3-Year Revenue Growth Rate : 46.80% (As of Jun. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Shield Therapeutics 3-Year Revenue Growth Rate?

Shield Therapeutics's Revenue per Share for the six months ended in Jun. 2023 was £0.01.

During the past 12 months, Shield Therapeutics's average Revenue per Share Growth Rate was -23.50% per year. During the past 3 years, the average Revenue per Share Growth Rate was 46.80% per year. During the past 5 years, the average Revenue per Share Growth Rate was 1.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 9 years, the highest 3-Year average Revenue per Share Growth Rate of Shield Therapeutics was 142.90% per year. The lowest was -58.60% per year. And the median was 36.40% per year.

Competitive Comparison of Shield Therapeutics's 3-Year Revenue Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Shield Therapeutics's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shield Therapeutics's 3-Year Revenue Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shield Therapeutics's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Shield Therapeutics's 3-Year Revenue Growth Rate falls into.

Shield Therapeutics 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Shield Therapeutics (LSE:STX) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Shield Therapeutics 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Shield Therapeutics's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Shield Therapeutics (LSE:STX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shield Therapeutics PLC (LSE:STX) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

SHIEF:USA 1JS:Germany

Address

Northern Design Centre, Baltic Business Quarter, Gateshead Quays, Newcastle, GBR, NE8 3DF

Website

https://www.shieldtherapeutics.com

Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. The company's operating segments are based on key products including Accrufer/Feraccru, used as a novel oral treatment for iron deficiency anemia in patients, which is commercially available, and PT20 used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from Feraccru segment.